2005 Fiscal Year Final Research Report Summary
Clinicopathological features of IL-6 expression in non-small cell lung carcinoma
| Project/Area Number |
16591385
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
IIZASA Toshihiko Chiba University, Graduate School of Medicine, associate professor, 大学院・医学研究院, 助教授 (10272303)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
FUJISAWA Takehiko Chiba University, Graduate School of Medicine, Professor, 大学院・医学研究院, 教授 (80110328)
SHIBUYA Kiyoshi Chiba University, Hospital, Assistant professor, 医学部附属病院, 講師 (20302565)
SUZUKI Makoto Chiba University, Hospital, Instructor, 医学部附属病院, 助手 (80312940)
IYODA Akira Chiba University, Hospital, Instructor, 医学部附属病院, 助手 (10302548)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Keywords | Non-small cell lung carcinoma / IL-6 / Immunotherapy / Gene therapy / Microarray / Decoy Oligonucleotides |
|---|
| Research Abstract |
OBJECTIVES
Expression of Interleukin-6 (IL-6) is involved in various malignant tumors. We evaluated preoperative serum IL-6 and immunohistochemically stained excised samples from 90 patients with non-small cell lung cancer (NSCLC), in order to analyze the correlation between serum IL-6 and expression of IL-6 in the tumor samples. We also investigated 209 resected samples of NSCLC using immunohistochemical staining of IL-6 to evaluate the influence of expression of IL-6 on the long-term survival and clinical features of patients with NSCLC.
METHODS
This study looked at 90 patients with primary NSCLC who underwent surgery between 2001 and 2003. Preoperative serum IL-6 samples from patients were measured with chemiluminescent enzyme immunoassay (CLEIA) and tumor samples were immunohistochemically stained with catalyzed signal amplification (CSA) to IL-6. We statistically analyzed these results and compared them with gender, age, smoking status, white blood cell count (WBC), C-reactive protei
… More
n (CRP), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), cytokeratin 19 fragment (CYFRA21-1), histology, tumor size, lymph node metastasis, and postoperative stage. Survival rates were calculated using the Kaplan-Meier method (Experiment 1). Secondly we retrospectively analyzed another population that consisted of 209 patients with primary NSCLC who underwent surgery between 1994 and 1996 (Experiment 2).
RESULTS
Exp.1 The serum concentrations of IL-6 were elevated in 43 of 90 cases (47.7%) compared to the normal upper limit. Positive staining of anti-IL-6 antibody occurred in 23 of 90 cases (25.5%). The prognosis of NSCLC patients with positive immunohistochemical staining was significantly worse compared to those with negative staining in a univariate analysis. In cases of elevated serum IL-6, those with T2, T3, or T4 status, and those with N1, N2, or N3 also had a poorer prognosis than the normal cases, T1 and N0, respectively. Multivariate analysis indicated that tumor size and overexpression of IL-6 were independent prognostic factors. Exp.2 Thirty-three of 209 patients (16%) with NSCLC expressed IL-6 positive immunostaining. Multivariate analysis indicated that the overexpression of IL-6 was also an independent prognostic factor as in Exp. 1.
CONCLUSION
We concluded that the expression of IL-6 in tumor tissues correlated with the concentration of serum IL-6,tumor progression and overall survival in NSCLC. Overexpression of IL-6 could be a poor prognostic factor in patients with NSCLC. Less
|
Research Products
(2 results)
